Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares ended Tuesday trading at $3.20, then gapped up to open at $3.60 before closing at $3.57. Volumes were heavy for the thinly traded micro-cap. NYMX has an average daily volume figure of 119,000 but today over 1.8 million shares traded – over 15 times normal. It should be noted that NYMX shares are, normally, fairly calm for a biopharmaceutical company. Nymox has a Beta of less than 1 which is indicative of stocks with a lower volatility than the overall market.
Today’s volatility was motivated by an update provided today by Nymox Pharmaceutical Corporation (NASDAQ:NYMX) on the company’s development activities for Fexapotide Triflutate – its new drug for prostate enlargement. The company is very pleased with the progress it has made, which is in line with its previous timeline announcements. Nymox now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Nymox’s new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Nymox has drug technology for other indications such as E. coli infection, Alzheimer’s disease, oncology, and infectious disease.
In Early 2015, NYMX shares were trading below $0.50 and today they are trying to break out permanently over $4. Over the years Nymox sales have declined modestly. In 2011 the company reported sales of $3.1 million and that number fell to $2.8 million by 2015. Shareholders of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have had EPS losses every year since 2011 when the loss was -$0.30. That loss shrank, but stayed negative until in2014, Nymox posted a loss of -$0.13. Then in 2015 an EPS loss of -$0.48 was posted. No firms or analysts cover Nymox Pharmaceutical Corporation (NASDAQ:NYMX).
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.